Log In
Print
BCIQ
Print
Print this Print this
 

RBX2660

  Manage Alerts
Collapse Summary General Information
Company Rebiotix Inc.
DescriptionIntestinal microbiota suspension
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPhase II
Standard IndicationClostridium
Indication DetailsTreat recurrent Clostridium difficile infection; Treat recurrent Clostridium difficile-associated diarrhea (CDAD)
Regulatory Designation

U.S. - Fast Track (Treat recurrent Clostridium difficile infection)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today